FDA Approval of GOMEKLI™ (mirdametinib)

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN FDA Approval of GOMEKLI™ (mirdametinib) - Neurofibromatosis Network

Leading NF Advocacy
Building NF Community

Author: NF Network, SpringWorks

Published On: 1/12/2025

The U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib). This is SpringWorks’ MEK inhibitor, for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN).

Please click here for the SpringWorks press release. In addition, the full prescribing information can be found at  https://springworkstx.com.

Want to view archived newsletters? Click Here!